Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.48 |
| ▸ | MET | P08581 | 11/20 | 0.47 |
| ▸ | AXL | P30530 | 6/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174159 | 0.88 | PDGFRA (0.59) | KDRPDGFRAMETAXLFGFR2 | |
| SCHEMBL29487188 | 0.88 | PDGFRA (0.59) | KDRPDGFRAMETAXLFGFR2 | |
| SCHEMBL31554535 | 0.86 | FLT3 (0.54) | FLT3KDRPDGFRAMETAXL | |
| SCHEMBL5050761 | 0.85 | MET (0.58) | FLT3KDRPDGFRAMET | |
| SCHEMBL371889 | 0.84 | MET (0.60) | FLT3KDRPDGFRAMETAXL | |
| SCHEMBL10254472 | 0.84 | FLT3 (0.49) | FLT3KDRPDGFRAMETAXL | |
| SCHEMBL372055 | 0.84 | MET (0.47) | FLT3KDRPDGFRAMETAXL | |
| SCHEMBL12635542 | 0.83 | MET (0.53) | KDRPDGFRAMETAXLFGFR2 | |
| SCHEMBL20032555 | 0.83 | PDGFRA (0.53) | FLT3KDRPDGFRAMETAXL | |
| SCHEMBL14310929 | 0.83 | MET (0.55) | FLT3KDRPDGFRAMETAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099962-A1 | NAPHTHYRIDINE COMPOUNDS, MEDICAL COMBINATIONS AND USE THEREOF | NANJING NATINEFY PHARMATECH CO., LTD. (CN) | 2018-04-12 | — | — | US | disclosed |
| US-9938274-B1 | Naphthyridine compounds, medical combinations and use thereof | NANJING NATINEFY PHARMATECH CO., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099962-A1 | NAPHTHYRIDINE COMPOUNDS, MEDICAL COMBINATIONS AND USE THEREOF | NPM1, NEK4, NME1 | FLT3 158/4885KDR 2288/4885PDGFRA 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.